Serving returns

How Ally Bridge expects to build on top of WuXi arbitrage play

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with the listing of WuXi's biologics unit in Hong Kong this year, the question is what will be its next moves to generate outsized returns for its investors.

Ally Bridge, which has about $1.5 billion under management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of which should come this half.

The firm also says it is working on new private equity deals that will rival WuXi in terms of size and impact.

Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund. But founder and CEO Frank Yu did share with BioCentury the portfolio companies the firm hopes will join the ranks of ear disorder company Otonomy Inc., a big win from 2015, and Tesaro Inc., the winner so far this year.

The task of maintaining its biotech returns could be challenging. Two of the firm's three public biotech investments in the first half already have at least doubled in price. In addition, Ally Bridge is hoping for a win in Alzheimer's disease, a space that is rife with failure, as well as the ability of several portfolio companies to differentiate themselves in the intensely crowded field of immuno-oncology.

"We had a nice hit with Otonomy and people said we were lucky. Then we did it again with Tesaro," said Yu. "People also said WuXi was a one-off big deal, but we're working on several of similar size and potentially higher

Read the full 3064 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE